Belt and Road Summit 2025- Deal-making

10 – 16 Sept 2025 | China (Hong Kong)

ProjectUpdated on 25 August 2025

A breakthrough therapy project for the treatment of neurodegeneration to unlock a $60B+ market

David Guan

CEO at SunRegen Healthcare AG

REINACH BL, Switzerland

About

SunRegen is a Swiss biopharmaceutical pioneer developing the world’s first oral neuro-rescuing therapy with the potential to treat retinal and CNS neurodegenerative diseases. Backed by Nobel-recognized science, robust preclinical data, and a $60B+ market opportunity, SBC003 represents a rare investment opportunity to support a first-in-class therapy with super blockbuster potential.

Project Location

  • Switzerland

Project Format

  • Private Project

ESG (Environmental, Social, and Governance)

  • No

Project Stage

  • Feasibility Study Completed

Main Project Sector

  • Technology

Technology

  • Health Technology

Total Project Value

  • 50,000,001 USD or above

Investment Capital Required

  • 10,000,001 to 25,000,000 USD

Interested Format of Cooperation

  • Joint Venture
  • Open for Negotiation
  • R&D Cooperation

Preferred Financing Model

  • Equity
  • Open for negotiation

Previous Funding Stage

  • Seed & Pre-Series

Return on Investment

200

Main Service(s) Required

  • Professional Services

Organisation

SunRegen Healthcare AG

Reinach, Switzerland

Similar opportunities

  • Project

    Build and Buy Studio

    • No
    • None
    • Equity
    • Operations
    • Manufacturing
    • Private Project
    • Financial Services
    • Open for Negotiation
    • Open for negotiation
    • Professional Services
    • 7,500,001 to 10,000,000 USD
    • 10,000,001 to 25,000,000 USD

    Mark Harrison

    CEO and Founder at Wealth Matrix

    London, United Kingdom

  • Project

    AI & MAPIS Enable Portable Non-Invasive Blood Glucose Monitoring

    • No
    • None
    • Technology
    • Joint Venture
    • Private Project
    • R&D Cooperation
    • Health Technology
    • Financial Services
    • Open for Negotiation
    • Open for negotiation
    • Minority Shareholdings
    • Feasibility Study Completed
    • 10,000,001 to 25,000,000 USD
    • 10,000,001 to 25,000,000 USD

    Ryan Jing

    CEO at TechInu Inc.

    Toronto, Canada

  • Project

    Synhealer

    • No
    • None
    • Bio-Tech
    • Technology
    • Joint Venture
    • R&D Cooperation
    • Project Planning
    • Health Technology
    • Financial Services
    • Open for Negotiation
    • Open for negotiation
    • Professional Services
    • 1,000,001 to 2,500,000 USD
    • 2,500,001 to 5,000,000 USD
    • Public-Private Partnership Project

    Daisy Tan

    Business Development Manager at InnoHK Centre for Translational Stem Cell Biology

    Hong Kong, China (Hong Kong)